RE:RE:RE:RE:RE:Zero enrollment updateThere is a lot we agree on AP.
Baxter has clearly shown they want to bring PMX to market. They've invested 7.5M for 40- 50% of PMX's future revenue, and in their KidneyCo presentation it's clear.
And even though Baxter does not list PMX in it's "near term" launches for 2023/ 2024 (link below), I'm sure they'd like it to be available to sell now. It is easy to see Baxter getting fed up with Spectral's inability to run the Tigris trial in a professional, timely manner- and stepping in.
The problem with that scenario for all of us shareholders is that an Unapproved PMX has a fraction of the value- as one with the FDA stamp of approval. There is no arguing otherwise.
So how is getting partial value an acceptable outcome for an investor?
We are not paying Seto or Kellum lousy salleries for their lousy enrollment!
Can we not- as the owners who fund this company and trial- demand actual results for our million a month burn? Do we not want full value?
I'll add, on your point about the millions of PSU Seto and Kellum gave to themselves to help incentivize them to DO THEIR JOBS. I fully expect them to update and move the goalposts. They are in no way hitting those deadlines- so modified dates or a whole new slew of options are about to be stuffed in their greedy mitts any day- bet on it.
Baxter Presentation Pg. 11
https://s22.q4cdn.com/911189824/files/doc_presentations/2023/Baxter-Investor-Announcement-010623.pdf